2024-02-14 22:52:09 ET
Aytu BioPharma, Inc. (AYTU)
Q2 2024 Earnings Conference Call
February 14, 2024 16:30 ET
Company Participants
Roger Weiss - Investor Relations
Joshua Disbrow - Chief Executive Officer
Mark Oki - Chief Financial Officer
Conference Call Participants
Naz Rahman - Maxim Group
Presentation
Operator
Greetings. Welcome to the Aytu BioPharma Fiscal 2024 Q2 Earnings Call. [Operator Instructions] Please note, this conference is being recorded. I will now turn the conference over to your host, Roger Weiss. You may begin.
Roger Weiss
Good afternoon, everyone and thank you for joining us for Aytu BioPharma's fiscal 2024 second quarter financial and operational results conference call for the period ended December 31, 2023. Joining us on today's call is Aytu's CEO, Josh Disbrow; and the company's Chief Financial Officer, Mark Oki. At the conclusion of today's prepared remarks, we'll open the call for a question-and-answer session. I'd like to remind everyone that today's call is being recorded. A replay of today's call will be available by using the telephone numbers and conference ID provided in the press release and issued earlier today.
Finally, I'd like to call your attention to the Safe Harbor Disclosure regarding forward-looking information. The conference call today will contain certain forward-looking statements, including statements regarding the goals, strategies, beliefs, expectations and future potential operating results of Aytu BioPharma. Although management believes these statements are reasonable based on estimates, assumptions and projections as of today, these statements are not guarantees of future performance. Time-sensitive information may no longer be accurate at the time of any telephonic or webcast replay. Actual results may differ materially as a result of risks, uncertainties and other factors, including but not limited to, the factors set forth in the company's filings with the SEC. Aytu undertakes no obligation to update or revise any of these forward-looking statements....
Read the full article on Seeking Alpha
For further details see:
Aytu BioPharma, Inc. (AYTU) Q2 2024 Earnings Call Transcript